Clinical Scorecard: Influence of Timing on Breast Volume in Trans Women: The Role of Testosterone Suppression and Puberty Management
At a Glance
Category
Detail
Condition
Breast development in transgender women undergoing gender-affirming hormone therapy (GAHT)
Key Mechanisms
Testosterone exposure during puberty, puberty suppression (PS) with GnRHa, estradiol therapy
Target Population
Transgender women initiating GAHT during adolescence or adulthood
Care Setting
Tertiary gender identity clinics
Key Highlights
Early puberty suppression (PS) with GnRHa does not increase breast volume compared to late PS or no PS prior to GAHT.
Median breast volume after GAHT is typically small (bra cup size < A), but most trans women report satisfaction with breast size.
Testosterone exposure during puberty does not appear to negatively affect breast volume after subsequent GAHT.
Guideline-Based Recommendations
Diagnosis
Diagnose gender dysphoria in adolescents and adults to guide timing of hormone therapy initiation.
Management
Use GnRHa for puberty suppression in adolescents to halt undesired male puberty changes.
Initiate estradiol therapy after PS with consideration of gradual dose increase to mimic physiological female puberty.
Combine anti-androgens and estrogen therapy as GAHT to induce feminization including breast development.
Monitoring & Follow-up
Measure breast volume using 3D scanning and assess patient satisfaction with breast development.
Adjust breast volume assessments for body fat percentage to accurately evaluate breast growth.
Risks
Be aware that limited breast development may lead to dissatisfaction and consideration of breast augmentation surgery.
Monitor for potential irreversible chest structural changes if puberty suppression is delayed.
Patient & Prescribing Data
Trans women aged 17-57 years receiving GAHT with or without prior puberty suppression.
Breast volume differences between early PS, late PS, and adult GAHT groups are minimal after adjusting for fat percentage; majority are satisfied with breast size despite limited volume.
Clinical Best Practices
Consider early initiation of puberty suppression to prevent undesired male secondary sexual characteristics but counsel that it may not increase breast volume.
Use a gradual estradiol dose increase during puberty induction to potentially optimize breast development.
Regularly assess patient satisfaction with breast development to guide discussions about possible breast augmentation.
Provide individualized hormone therapy plans considering timing of PS and estradiol dosing.
by Lidewij S Boogers, Sebastiaan A Sardo Infirri, Asma Bouchareb, Benthe A M Dijkman, Danithsia Helder, Christel J M de Blok, Niels P T J Liberton, Martin den Heijer, A S Paul van Trotsenburg, Koen M A Dreijerink, Chantal M Wiepjes, Sabine E Hannema
